The aim of this retrospective cohort study was to assess the cumulative incidence and predictive factors for intracerebral hemorrhagic stroke after the termination of interferon (IFN) therapy in Japanese patients with hepatitis C virus (HCV). A total of 4,649 HCV-positive patients treated with IFN were enrolled. The primary goal is the first onset of intracerebral hemorrhagic stroke. The mean observation period was 8.0 years. Evaluation was performed using the Kaplan-Meier method and the Cox proportional hazard model. A P-value of less than 0.05 was considered statistically significant. A total of 28 developed intracerebral hemorrhagic stroke. The cumulative incidence of intracerebral hemorrhagic stroke was 0.3% at 5 years, 0.8% at 10 years, and 1.7% at 15 years. Intracerebral hemorrhagic stroke occurred when patients had age increments of 10 years (hazard ratio: 2.77; 95% confidence interval (CI) 1.48-5.18; P=0.001), hypertension (hazard ratio: 2.30; 95% CI 1.09-4.83; P=0.021), liver cirrhosis (hazard ratio: 4.50; 95% CI 2.07-9.78; P<0.001), and HCV non-clearance (hazard ratio: 3.22; 95% CI 1.22-8.53; P=0.018). On the intracerebral hemorrhagic stroke based on the difference of liver fibrosis and efficacy of IFN therapy, HCV clearance reduced to 24.3% (1/4.11) compared to HCV non-clearance in cirrhotic patients (P=0.040). In conclusion, HCV clearance reduced the development of intracerebral hemorrhagic stroke. In particular, HCV clearance reduced intracerebral hemorrhagic stroke to about one-fourth in cirrhotic patients. © 2013 Wiley Periodicals, Inc.
CITATION STYLE
Arase, Y., Kobayashi, M., Kawamura, Y., Suzuki, F., Suzuki, Y., Akuta, N., … Kobayashi, T. (2014). Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C. Journal of Medical Virology, 86(1), 169–175. https://doi.org/10.1002/jmv.23777
Mendeley helps you to discover research relevant for your work.